Injectable anabolic androgenic steroid
Trenbolone Acetate
Trenbolone Acetate after one dose: 50% at ~2.5 days, 25% at 5 days, 12.5% at 7.5 days.
Drawn from the half-life in the app's model, ~2.5 days. The model's figures
- Compound
- Trenbolone Acetate
- Symbol
- TRA
- Family
- Other steroids
- Parts
- 13
- References
- 25
- Checked
- Last reviewed . Sources are listed below.
Overview
Trenbolone acetate (TBA) is the acetate of trenbolone, which the World Anti-Doping Agency names as 17ß-hydroxyestr-4,9,11-trien-3-one and a 2024 review describes as "a synthetic analogue of testosterone, belonging to the nandrolone group".2,3,4 In a 2026 survey study, Bonenti and colleagues describe trenbolone as "a synthetic AAS with high androgen‐receptor affinity, non‐aromatising properties and notable progestogenic activity" and note that it was "originally developed for veterinary growth promotion in cattle".5
A search of DailyMed on 16 November 2026 for trenbolone returned 22 records: 19 titled as implants of trenbolone acetate combined with estradiol (Revalor, Synovex and Component brands) and 3 titled as trenbolone acetate powder. The Revalor-S label describes an implant of 120 mg of trenbolone acetate and 24 mg of estradiol "for increased rate of weight gain and improved feed efficiency in growing beef steers fed in confinement for slaughter", and it states "Not for use in humans".1 The other 21 records were not read in full.
Authors of a 2014 case report from Tabriz University of Medical Sciences write that "the injectable Trenbolone acetate was originally adapted for use by bodybuilders from the dissolution of Finaplix H pellets", an ear implant used by cattle ranchers.6 A search of PubMed on 16 November 2026 for trenbolone in the title or summary text returned 715 records, and the same search limited to the clinical trial or randomized controlled trial publication types returned 24, whose titles all name livestock or livestock production. A search of ClinicalTrials.gov on 16 November 2026 for trenbolone returned 0 studies.
The human data cited below come from a 1967 intramuscular volunteer study summarised in WHO Food Additives Series 23, urine excretion studies in volunteers, a one-subject disposition study from 1991, surveys and interviews of people who use anabolic steroids, and case reports.4,7,8,5,9,6 The Moderate Evidence badge and the figures row show the app's own grade and figures, not conclusions of the sources.
How it works
Sources in this part
A 2010 review by Yarrow and colleagues in Steroids, from the Geriatric Research, Education and Clinical Center of the VA Medical Center in Gainesville, Florida, states that trenbolone "binds to androgen receptors (ARs) with approximately three times the affinity of testosterone" and that, compared with testosterone, it "appears to induce less growth in androgen-sensitive organs which highly express the 5alpha reductase enzyme".10 The review also states that trenbolone "has been shown to augment skeletal muscle mass and bone growth and reduce adiposity in a variety of mammalian species", and that its metabolism "provides a basis for future research evaluating its safety and efficacy" in conditions in humans.10
The 2010 review compares affinity with testosterone, whereas in a 2000 laboratory study from the Technical University of Munich (Bauer and colleagues, APMIS) 17beta-trenbolone had an affinity for the recombinant human androgen receptor similar to that of dihydrotestosterone and a slightly higher affinity than progesterone for the bovine uterine progestin receptor, so the two affinity comparisons are not the same measure.11
In a 2011 study in rats, not people, Yarrow and colleagues (American Journal of Physiology, Endocrinology and Metabolism) gave male F344 rats that had undergone orchiectomy or remained intact graded doses of trenbolone enanthate, supraphysiological testosterone enanthate or vehicle for 29 days.12 All trenbolone enanthate doses, like supraphysiological testosterone enanthate, "augmented androgen-sensitive levator ani/bulbocavernosus muscle mass by 35-40% above shams", and the lowest doses "successfully maintained prostate mass and hemoglobin concentrations at sham levels", while supraphysiological testosterone enanthate and high-dose trenbolone enanthate "elevated prostate mass by 84 and 68%, respectively".12 All trenbolone enanthate doses and supraphysiological testosterone enanthate also "produced a dose-dependent partial protection against orchiectomy-induced total and trabecular bone mineral density losses (P < 0.05) and visceral fat accumulation (P < 0.05)".12
In a 14-week dietary study in pigs (Ross and colleagues, 1980, as summarised in WHO Food Additives Series 25), serum testosterone and estradiol levels were "significantly decreased in males at 2 and 20 ppm TBA", an animal result.13 The same summary reports that "Cholesterol levels were significantly increased in males and females at 2.0 and 20 ppm", "Significant dose-related hematological effects were found (at week 12) in females receiving 2.0 or 20 ppm TBA", "Dose-related abnormalities were observed in the liver" (with testes, ovaries and uterus) at 2 and 20 ppm TBA, and that "One pig in the highest-dose group was sacrificed after developing a partial paralysis of the hindquarters during week 10".13
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2.5 days
- Bioavailability
- 95%
- Typical dose
- 50–400 mg/week
- Route
- IM
- Time to peak
- ~24 h
The figures row shows the app's values: a half-life of ~2.5 days (60 hours), bioavailability of 95%, a time to peak of ~24 h and the intramuscular route. No cited source reports a human half-life, bioavailability or time to peak of trenbolone acetate.
| Measure | App figure | Source figure |
|---|---|---|
| Half-life | ~2.5 days (60 h) | No cited source reports a half-life of trenbolone acetate in people. In two cows given 10 mg of tritium-labelled TBA intravenously, TBOH "disappeared from the blood (half-life, 1.5 hours)" between 3 and 8 hours, as summarised by JECFA. In two cows given 300 mg of labelled TBA as a subcutaneous implant at the base of the ear, "the half-life of disappearance from the implant was 68 - 84 days". 4 |
| Bioavailability | 95% | No cited source reports a bioavailability of trenbolone acetate. |
| Time to peak | ~24 h | No cited source reports a time to peak in people. In two male calves given 140 mg of TBA as a subcutaneous implant at the base of the right ear, urinary TBOH reached its maximum after 10 hours. 4 |
| Route | IM | The US cattle label describes a subcutaneous ear implant. The 2026 volunteer excretion studies used oral, transdermal and buccal administration, and the 1967 volunteer study summarised in WHO FAS 23 used intramuscular doses of 5 or 10 mg of TBA. 1,7,14,4 |
Spranger and Metzler (University of Kaiserslautern, Journal of Chromatography, 1991) followed "a human subject" after ingestion of tracer-labelled 17 beta-trenbolone at 0.04 mg/kg body weight: 54% of the administered radioactivity was in the urine after 26 h and 63% after 72 h.8 They write that "the disposition of 17 beta-trenbolone in humans differs significantly from that in rats", and the PubMed record reports no half-life.8
Deeper analysis: controlled excretion studies (Krombholz and colleagues, 2026)
Krombholz and colleagues at the German Sport University Cologne (Steroids, 2026) studied "the urinary excretion profile of trenbolone and its metabolites after oral, transdermal and buccal administration in healthy male volunteers", with urine collected over one week after 10 mg of trenbolone.7 The record names the compound as trenbolone, not trenbolone acetate, and does not give the number of volunteers.7 Two of the five authors are affiliated with the Crop Science Division of Bayer AG, and the authors declare that they have no known competing financial interests.7
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Krüskemper and colleagues, 1967, as summarised in WHO FAS 234 | Volunteer study of intramuscular TBA, as summarised by JECFA. | Male and female human volunteers; number not given in the summary. | 5 or 10 mg TBA intramuscularly every other day for 14 days. | At 5 mg nitrogen balance was disturbed, including retention of nitrogen; at 10 mg some women showed menstrual cycle disturbances and 17-ketosteroid excretion fell slightly but significantly; no effects on 17-hydroxycorticosteroid excretion; blood parameters (protein, cholesterol, coagulation factors, prothrombin and thrombin time) were unaffected. |
| Spranger and Metzler, 19918 | Disposition study of tracer-labelled 17 beta-trenbolone taken by mouth. | One human subject. | 0.04 mg/kg body weight; urine followed for 72 h. | 54% of the administered radioactivity in urine after 26 h and 63% after 72 h; 54% of urinary material was glucuronides, mostly 17 alpha-trenbolone, 17 beta-trenbolone and trendione. |
| Krombholz and colleagues, 2026 (Steroids)7 | Controlled excretion study by three routes; compound named trenbolone. | Healthy male volunteers; number not given in the record. | 10 mg of trenbolone orally, transdermally or by buccal route; urine for one week. | Metabolites detectable in all participants; buccal elimination faster and transdermal detectability longer than oral. |
| Krombholz and colleagues, 2026 (J Anal Toxicol)14 | Controlled excretion study, dermal application; compound named trenbolone. | Healthy male volunteers; number not given in the record. | Single dose of 50 µg to the forearm. | Epitrenbolone up to 2.6 ng/ml, detection window up to 3 days; detectable in all participants. |
| Bonenti and colleagues, 20265 | Cross-sectional online survey (Global Drug Survey 2024). | 1,146 men with past-year anabolic steroid use: 237 with injectable trenbolone use in the past 12 months, 909 without. | Self-reported past-12-month use; dose not analysed. | Seven of 8 psychosocial items (not "other") and 10 of 12 physical items (not breast size reduction or increase) were more common in the trenbolone group; heart 54.4% against 31.2% and liver 42.2% against 22.4% (both p < 0.001); chi-square comparisons with no adjustment described. |
| Piatkowski and colleagues, 202415 | Online survey with purposive and snowball sampling. | 282 males using anabolic steroids; 93 currently using trenbolone, 156 past users, 33 never users. | Trenbolone dose; units and length not given in the PubMed record. | After controlling for age and BMI, trenbolone dose was associated with higher verbal aggression (p=0.045). |
| Piatkowski and colleagues, 20239 | Qualitative interviews; the authors describe a narrative about trenbolone. | Subset of a larger qualitative study: 16 anabolic steroid users in whom trenbolone "played a central role". | Not applicable. | Trenbolone viewed as having the most deleterious consequences of all the steroids, with reported aggression, violent behaviour and impulsivity regulation issues. |
| Shahsavari Nia and colleagues, 20146 | Case report. | One 23-year-old male body builder. | Trenbolone acetate "in his daily diet since last year", from the patient's history; dose not stated. | Myocardial infarction with ST elevation in V1 to V6 and stenosis of the left anterior descending and left circumflex arteries; streptokinase, then a stent. |
| Kumar and colleagues, 201916 | Case report. | One 24-year-old man. | Four years of anabolic steroid use, most recently trenbolone acetate; dose not stated. | Acute pancreatitis that recurred after reuse of the same drug, with other causes ruled out. |
| Lizardo and colleagues, 202617 | Case report; compound named trenbolone. | One 41-year-old man. | Trenbolone use; dose and ester not stated. | Calcium 15 mg/dL, creatinine 6.02 mg/dL; malignancy, hyperparathyroidism and vitamin D toxicity ruled out; improved with fluids and pamidronate; the authors call trenbolone use "the most likely cause". |
| Anand and colleagues, 200618 | Case report. | One 21-year-old male bodybuilder. | Described as an overdose of Parabolan (trenbolone acetate); dose not stated. | Cholestasis, bilirubin up to 65.5 mg/dl; five MARS cycles; bilirubin 2 mg/dl at 2 months. |
Deeper analysis: Global Drug Survey 2024 comparison (Bonenti and colleagues, 2026)
Bonenti and colleagues, from the School of Public Health at the University of Queensland and collaborators, published a cross-sectional comparison in Drug and Alcohol Review in 2026 using the Global Drug Survey 2024, an "anonymous online survey" that was open from 10 January to 30 April 2024.5 The 1,146 men who reported past-year anabolic steroid use were grouped by injectable trenbolone use in the past 12 months: 237 in the trenbolone group and 909 in the non-trenbolone group.5 Participants ticked yes or no for concerns they perceived as resulting from their steroid use, and respondents were recruited through news outlets, social media and "collaborations with content creators and influencers".5
Anger or aggression was reported by 50 of 237 (21.1%) in the trenbolone group and 84 of 909 (9.2%) in the non-trenbolone group, and loss of interest in other things by 55 (23.2%) against 73 (8.0%), each with p < 0.001.5 No significant difference was seen for "other" psychosocial concerns (8.0% against 5.2%, p = 0.094) or for reduction or increase in breast size (p = 0.97 and p = 0.979).5 The groups also differed in how they used steroids: injectable use in the past 12 months was reported by 99.2% of the trenbolone group and 59.3% of the non-trenbolone group, and oral use by 79.7% against 38.4% (both p < 0.001).5 Gynecomastia was reported by 77 (32.5%) against 187 (20.6%), p < 0.001.5 The authors describe the trenbolone group as men who use trenbolone "alongside other AAS", and the comparisons are chi-square tests with no adjustment described.5
The authors write that "interpretation is limited by self‐reported, cross‐sectional data, which cannot establish causality", that "Outcomes represent perceived effects rather than clinically verified diagnoses", and that they "did not incorporate available dosing variables, such as weekly milligram ranges, cycle length, stacking patterns or prescription status", that "Recruitment strategies may over‐represent digitally connected consumers", and that "GDS is a self‐selecting survey". They also write that "The trenbolone group's substantially greater oral AAS involvement likely compounds this effect" in the discussion of liver stress.5 Funding is stated as a National Health and Medical Research Council Investigator Grant to the last author, one co-author is listed as contributing "data acquisition for the Global Drug Survey", and the authors declare no conflicts of interest.5 The last author, Piatkowski, is also first author of the 2023 interview study and the 2024 survey in the table.
Doses reported in studies and on labels
| Source | Subject | Dose and route | Note |
|---|---|---|---|
| US label, Revalor-S1 | Growing beef steers | 120 mg trenbolone acetate with 24 mg estradiol per implant, 6 pellets, under the skin of the ear | "Not for use in humans" |
| WHO FAS 23, volunteer study (Krüskemper and colleagues, 1967)4 | Male and female human volunteers | 5 or 10 mg TBA intramuscularly every other day for 14 days | Nitrogen balance disturbed at 5 mg; some women had menstrual cycle disturbances at 10 mg |
| JECFA acceptable daily intake13 | Acceptable daily intake set by JECFA | 0-0.02 µg/kg bw for TBA | Based on hormonal effects in a 14-week pig study, with a safety factor of 100 |
Sources in this part
The app's typical dose for trenbolone acetate is 50–400 mg/week; no cited source reports a weekly dose of trenbolone acetate for people, and the WHO FAS 23 summary reports intramuscular doses of 5 or 10 mg of TBA every other day for 14 days in volunteers.4 The Bonenti authors write that they "did not incorporate available dosing variables, such as weekly milligram ranges, cycle length, stacking patterns or prescription status", and the case reports do not state doses.5
Side effects reported
A 2024 review by Borecki and colleagues of the Medical University of Lodz (Endokrynologia Polska) states that "Trenbolone, like other AASs, are harmful, with 90% of users experiencing injurious side effects" and lists "severe acne and gynaecomastia affecting approximately one-third of all users, as well as excessive body hair, stretch marks, hypertension and cardiac arrhythmia". It adds that the drugs "are also subject to contamination, with use frequently resulting in local inflammation at the injection site, muscle adhesions and fibrosis, nerve damage or, in extreme cases, necrosis of the injection site".3
The case reports in the table describe myocardial infarction, acute pancreatitis that recurred on reuse, hypercalcemia with acute kidney injury and cholestasis; each concerns one person.6,16,17,18 In the hypercalcemia report the authors write that "trenbolone use was the most likely cause of hypercalcemia" after exclusions and that "dehydration could have been a contributing factor", and the man worked outdoors with difficulty maintaining hydration.17 A separate post-mortem report describes heart failure with cardiomegaly in a 60-year-old man who was described as "a long-term user of anabolic steroids", for whom there was "no anatomic pathology test"; the authors write that "Repetitive misuse of trenbolone can explain the advanced heart failure".19
In the 2023 interview study by Piatkowski and colleagues, which the authors describe as a "narrative", the 16 people were those for whom trenbolone "played a central role" in a larger qualitative study, and the authors write that "myth has developed among users with trenbolone reportedly having more dramatic effects on individuals".9 Trenbolone "was viewed as having the most deleterious consequences for those who used it", with reported aggression, violent behaviour and impulsivity regulation issues.9
For anabolic steroids and performance-enhancing drugs in general rather than trenbolone alone, an Endocrine Society scientific statement (Pope and colleagues, Endocrine Reviews, 2014) says that "PED use has been linked to an increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, endocrine, neurologic, infectious, hepatic, renal, and musculoskeletal disorders".20 A 2008 review by Kicman (British Journal of Pharmacology) states that "Doping with anabolic steroids can result in damage to health" and that "it is important not to exaggerate the medical risks associated with their administration for sporting or bodybuilding purposes but to emphasize to users that an attitude of personal invulnerability to their adverse effects is certainly misguided".21
Markers and detection in testing
Sources in this part
Urine testing for trenbolone targets the compound and metabolites such as epitrenbolone; Thevis and colleagues (German Sport University Cologne, Steroids, 2009) validated a liquid chromatography-tandem mass spectrometry method for trenbolone and six related compounds with "lower limits of detection (0.3-3ng/mL)".22 De Boer and colleagues (Biological Mass Spectrometry, 1991) identified the glucuronides of trenbolone and epitrenbolone "in three urine specimens out of 200 samples in routine doping control", and Ye and colleagues (Yao Xue Xue Bao, 1994) report epitrenbolone and possible hydroxy-trenbolone as the main metabolites in a trenbolone acetate positive urine.23,24 In a post-mortem case, Gheddar and colleagues report trenbolone concentrations of 3.9, 3.2, 231 and lower than 0.5 ng/mL in femoral blood, cardiac blood, bile and vitreous humor, and 9 pg/mg in head hair, which they interpret as "repetitive exposures".19
Regulatory and anti-doping status
The WADA 2026 Prohibited List places anabolic androgenic steroids in section S1, "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and names trenbolone among the examples listed under S1.1 for anabolic androgenic steroids "when administered exogenously". The list also covers "other substances with a similar chemical structure or similar biological effect(s) including their esters", and it names trenbolone, not trenbolone acetate.2 In the United States, 21 CFR 1308.13(f) lists anabolic steroids in Schedule III "Unless specifically excepted or unless listed in another schedule" for "any substance meeting the definition of anabolic steroid as set forth in § 1300.01", including "its salts, esters and ethers" of the substances listed, and item (86) is trenbolone.25
The Revalor-S label is for cattle and states "Do not use in animals intended for subsequent breeding, or in dairy cows", "Implant pellets subcutaneously in ear only" and "Not for use in humans".1 The cited sources do not cover the regulation of trenbolone acetate in other countries.
What is not known
- No cited source reports a half-life, bioavailability or time to peak of trenbolone acetate in people, so the app's ~2.5 days, 95% and ~24 h are not matched by a source.
- No cited source gives a weekly dose of trenbolone acetate for people; the only human dosing is the intramuscular 5 or 10 mg every other day for 14 days in volunteers summarised in WHO FAS 23, and the survey authors did not analyse available dosing variables.5
- Several records name the compound as trenbolone or injectable trenbolone without the ester, so which results apply to the acetate is not stated.7,5,17
- The records read for the Yarrow 2010 review, the Yarrow 2011 rat study and the Bauer 2000 binding study do not state their funding.10,12,11
- Case reports describe single people, and the survey results are self-reported and cross-sectional, so the sources do not give how often any effect occurs.5
Frequently asked questions
What is the half-life of trenbolone acetate?
The app's half-life for trenbolone acetate is ~2.5 days (60 hours), and none of the cited sources reports a half-life of trenbolone acetate in people.
Is trenbolone acetate banned by WADA?
Yes, trenbolone is named among the anabolic androgenic steroids in section S1.1 of the WADA 2026 Prohibited List, which is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and the list also covers "other substances with a similar chemical structure or similar biological effect(s) including their esters".2
Is trenbolone acetate approved for use in people?
The Revalor-S label is for a cattle implant and states "Not for use in humans".1
Is trenbolone acetate a controlled substance in the US?
Yes, subject to the definition and exceptions in the rule: 21 CFR 1308.13(f) lists trenbolone among the Schedule III anabolic steroids "Unless specifically excepted or unless listed in another schedule" for substances meeting the definition in § 1300.01, including its salts, esters and ethers.25
How long can trenbolone be detected in urine?
No cited source gives a detection window after trenbolone acetate is injected. In a 2026 study of a single 50 µg dermal dose, a trace-exposure scenario, in healthy male volunteers, epitrenbolone reached up to 2.6 ng/ml with a detection window of up to 3 days.14
What side effects are reported with trenbolone acetate?
A 2024 review lists severe acne and gynaecomastia affecting approximately one-third of all users, excessive body hair, stretch marks, hypertension and cardiac arrhythmia, says the drugs "are also subject to contamination", and says many effects remain unknown.3 Case reports describe myocardial infarction, pancreatitis, hypercalcemia with acute kidney injury and cholestasis in single people, with causes as attributed by the authors.6,16,17,18
Do people who use trenbolone report more mood and heart concerns?
In a 2026 self-selected online survey of 1,146 men with past-year steroid use, 21.1% of 237 men with injectable trenbolone use reported anger or aggression against 9.2% of 909 without it, and 54.4% reported a perceived negative impact on the heart against 31.2% (both p < 0.001), without adjustment for other differences.5 The trenbolone group more often used injectable (99.2% against 59.3%) and oral (79.7% against 38.4%) steroids.5 The authors state that the data are self-reported and cross-sectional and "cannot establish causality".5
Does trenbolone aromatize to estrogen?
Two cited papers describe trenbolone as non-aromatising or as having reduced estrogenic activity, as descriptions rather than measurements: Bonenti and colleagues in their introduction, and a 2010 review in its title ("reduced androgenic and estrogenic activity"). In the 2026 survey, gynecomastia was reported by 77 of 237 (32.5%) men in the trenbolone group against 187 of 909 (20.6%), p < 0.001, and a 2024 review gives gynaecomastia in approximately one-third of users.5,10
Has trenbolone acetate been tested in clinical trials?
A ClinicalTrials.gov search for trenbolone returned 0 studies on 16 November 2026, and the 24 PubMed records for trenbolone in the clinical trial or randomized controlled trial publication types all have titles naming livestock or livestock production. These searches do not include the 1967 volunteer study of intramuscular TBA, 5 or 10 mg every other day for 14 days, that WHO FAS 23 summarises.
Guides, tools and comparisons
References
- Merck Sharp & Dohme Corp. Revalor-S (trenbolone acetate and estradiol) implant, US veterinary label. DailyMed, set ID d173d667-86b5-4414-b6d2-76a1f95ec456, 2025. DailyMed label
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA, in effect 1 January 2026. WADA 2026 list
- Borecki R, Byczkiewicz P, Slowikowska-Hilczer J. Impact of trenbolone on selected organs. Endokrynol Pol 2024. PMID 38887114
- Joint FAO/WHO Expert Committee on Food Additives. Trenbolone acetate. WHO Food Additives Series 23, monograph 645. WHO, 1988. WHO FAS 23
- Bonenti B, Ahmadinejad B, Puljevic C, et al. The Trenbolo(g)ne Sandwich: an international study comparing health harms among men who use anabolic-androgenic steroids with and without trenbolone. Drug Alcohol Rev 2026. PMC13112052
- Shahsavari Nia K, Rahmani F, Ebrahimi Bakhtavar H, et al. A young man with myocardial infarction due to trenbolone acetate; a case report. Emerg (Tehran) 2014. PMC4614617
- Krombholz S, Piper T, Lagojda A, et al. The influence of the route of drug administration on the metabolic profile of trenbolone in doping control urine samples. Steroids 2026. PMID 41224119
- Spranger B, Metzler M. Disposition of 17 beta-trenbolone in humans. J Chromatogr 1991. PMID 1874853
- Piatkowski TM, Neumann DL, Dunn M. "My mind pretty much went to mush": a qualitative exploration of trenbolone in the performance and image enhancing drug community. Drug Alcohol Rev 2023. PMID 36992616
- Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010. PMID 20138077
- Bauer ER, Daxenberger A, Petri T, Sauerwein H, Meyer HH. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS 2000. PMID 11252818
- Yarrow JF, Conover CF, McCoy SC, et al. 17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 2011. PMID 21266670
- Joint FAO/WHO Expert Committee on Food Additives. Trenbolone acetate. WHO Food Additives Series 25, monograph 672. WHO, 1990. WHO FAS 25
- Krombholz S, Angelis YA, Fussholler G, Thevis M. Urinary detection and metabolite profiles of trenbolone and metenolone following trace-level dermal exposure. J Anal Toxicol 2026. PMID 42758135
- Piatkowski T, De Andrade D, Neumann D, Tisdale C, Dunn M. Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroids. Int J Drug Policy 2024. PMID 39486244
- Kumar V, Issa D, Smallfield G, Bouhaidar D. Acute pancreatitis secondary to the use of the anabolic steroid trenbolone acetate. Clin Toxicol (Phila) 2019. PMID 30101635
- Lizardo KC, Merchant S, Drone E. Hypercalcemia from trenbolone use: a case report. Cureus 2026. PMC12949651
- Anand JS, Chodorowski Z, Hajduk A, Waldman W. Cholestasis induced by parabolan successfully treated with the molecular adsorbent recirculating system. ASAIO J 2006. PMID 16436902
- Gheddar L, Pelissier AL, Desfeux J, et al. Testing for trenbolone, an anabolic steroid, in biological fluids and head hair in a post-mortem case. J Anal Toxicol 2021. PMID 34410404
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014. PMID 24423981
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMID 18500378
- Thevis M, Guddat S, Schanzer W. Doping control analysis of trenbolone and related compounds using liquid chromatography-tandem mass spectrometry. Steroids 2009. PMID 19007801
- de Boer D, Gainza Bernal ME, van Ooyen RD, Maes RA. The analysis of trenbolone and the human urinary metabolites of trenbolone acetate by gas chromatography/mass spectrometry and gas chromatography/tandem mass spectrometry. Biol Mass Spectrom 1991. PMID 1768702
- Ye L, Zhang CJ, Zhang YZ, Liu X. Trenbolone and its metabolites in human urine by GC/MS analysis (in Chinese). Yao Xue Xue Bao 1994. PMID 8036900
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations, current to November 2026. 21 CFR 1308.13